{"title": "Serial interval of novel coronavirus (2019-nCoV) infections", "doi": "10.1101/2020.02.03.20019497", "citation_id": "2020.02.03.20019497v2", "date": "2020-02-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.03.20019497", "abstract": "<p>Objective: To estimate the serial interval of novel coronavirus (COVID-19) from information on 28 infector-infectee pairs.\nMethods: We collected dates of illness onset for primary cases (infectors) and secondary cases (infectees) from published research articles and case investigation reports. We subjectively ranked the credibility of the data and performed analyses on both the full dataset (n=28) and a subset of pairs with highest certainty in reporting (n=18). In addition, we adjusting for right truncation of the data as the epidemic is still in its growth phase.\nResults: Accounting for right truncation and analyzing all pairs, we estimated the median serial interval at 4.0 days (95% credible interval [CrI]: 3.1, 4.9). Limiting our data to only the most certain pairs, the median serial interval was estimated at 4.6 days (95% CrI: 3.5, 5.9).\nConclusions: The serial interval of COVID-19 is shorter than its median incubation period. This suggests that a substantial proportion of secondary transmission may occur prior to illness onset. The COVID-19 serial interval is also shorter than the serial interval of severe acute respiratory syndrome (SARS), indicating that calculations made using the SARS serial interval may introduce bias.</p>", "twitter_description": "Objective: To estimate the serial interval of novel coronavirus (COVID-19) from information on 28 infector-infectee pairs. Methods: We collected dates of illness onset for primary cases (infectors) and secondary cases (infectees) from published research articles and case investigation reports. We subjectively ranked the credibility of the data and performed analyses on both the full dataset (n=28) and a subset of pairs with highest certainty in reporting (n=18). In addition, we adjusting for right truncation of the data as the epidemic is still in its growth phase. Results: Accounting for right truncation and analyzing all pairs, we estimated the median serial interval at 4.0 days (95% credible interval [CrI]: 3.1, 4.9). Limiting our data to only the most certain pairs, the median serial interval was estimated at 4.6 days (95% CrI: 3.5, 5.9). Conclusions: The serial interval of COVID-19 is shorter than its median incubation period. This suggests that a substantial proportion of secondary transmission may occur prior to illness onset. The COVID-19 serial interval is also shorter than the serial interval of severe acute respiratory syndrome (SARS), indicating that calculations made using the SARS serial interval may introduce bias.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nH.N. received funding support from Japan Agency for Medical Research and Development [grant number: JP18fk0108050] the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI in Japanese abbreviation) grant nos. 17H04701, 17H05808, 18H04895 and 19H01074, and the Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST) program [grant number: JPMJCR1413].\u3000NML receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan. \n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe data can be obtained from Supplementary Table.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20019497v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20019497v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20019497v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.03.20019497.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.03.20019497v2", "access_rights": "restricted", "authors": ["Hiroshi Nishiura", "Natalie M Linton", "Andrei R. Akhmetzhanov"]}